Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Manisha H. Shah, MD, Panel Chair, has disclosed that she has received grant/research support from Eisai Inc., Loxo Oncology, Inc., and Merck & Co., Inc., and that she has served on the advisory board of Loxo Oncology, Inc. and Novartis Pharmaceuticals Corporation.
Whitney S. Goldner, MD, Panel Vice Chair, has disclosed that she has received other financial benefit from AstraZeneca Pharmaceuticals LP, Eisai Inc., and
Roche Laboratories, Inc.
Thorvardur R. Halfdanarson, MD, Panel Member, has disclosed that he has received grant/research support from Agios, Inc., Ipsen, and ArQule, Inc.
Emily Bergsland, MD, Panel Member, has disclosed that she has received grant/research support from and has served as a consultant for Merck & Co., Inc., Lexicon Pharmaceuticals, Inc./Novartis Pharmaceuticals Corporation, and MOREHealth. She has also served on the board for Lexicon Pharmaceuticals, Inc. and Ipsen.
Jordan D. Berlin, MD, Panel Member, has disclosed that he has received grant/research support from EMD Serono, Inc.; Symphogen Inc.; Incyte Corporation; BeiGene, Ltd.; Roche Laboratories, Inc.; Five Prime Therapeutics, Inc.; and Karyopharm Therapeutics Inc. He has also served on the advisory board for ARMO BioSciences, Inc.; Rafael Pharmaceuticals, Inc.; Five Prime Therapeutics, Inc.; EMD Serono, Inc.; Erytech Pharma; Symphogen Inc.; Celgene Corporation; AbbVie Inc.; AstraZeneca Pharmaceuticals LP; and Gritstone Oncology.
Daniel Halperin, MD, Panel Member, has disclosed that he has received consulting fees/honoraria from AbbVie, Inc., Ipsen, Lexion Pharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation; and that he has received grant/research support from Genentech, Inc., Ipsen, Novartis Pharmaceuticals Corporation, and Tarveda Therapeutics.
Jennifer Chan, MD, Panel Member, has disclosed that she has received consulting fees/honoraria from Advanced Accelerator Applications USA, Inc., Ipsen, and Novartis Pharmaceuticals Corporation, and that she has equity interest/stock options in Merck & Co., Inc.
Jennifer L. Burns, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Ndiya Ogba, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
Griselda Zuccarino-Catania, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.